Effects of phosphodiesterase inhibition on skeletal muscle vasculature.
The pathophysiology of the syndrome of congestive heart failure (CHF) includes 2 major components that closely interact. The first one is a reduction in ventricular performance, which is manifested initially during exercise and is later present at rest. The second one involves abnormalities of the peripheral circulation and organs, which become gradually more prominent and lead ultimately to symptoms. The exercise capacity of patients with chronic CHF is limited not only by an inadequate increase in cardiac output and an excessive increase in ventricular filling pressure, but also by a fixed vasodilatory response to exercise. Although the role of increased activity of the sympathetic and renin-angiotensin-aldosterone systems in the derangements of the peripheral circulation has been extensively investigated, the structural abnormalities of the arterial wall have received little emphasis in patients with CHF. Chronic reduction of the cardiac output may lead to endothelium-dependent reduction in arterial diameter and vasomotor response, which may in turn increase systemic vascular resistance and further reduce cardiac output. Therapeutic agents should be characterized by their acute and chronic effects not only on ventricular performance, but also on the peripheral circulation. More specifically, when one is concerned with the effect of a therapeutic intervention on exercise capacity, evaluation of its direct and indirect effects on the skeletal muscle vasculature is particularly important. Accordingly, the effects of phosphodiesterase inhibition on vascular smooth muscle tone and skeletal muscle vasculature are reviewed. In addition, the potential of phosphodiesterase inhibition to reverse structural abnormalities of the arterial wall is discussed.
LeJemtel
T H
TH
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461.
Scortichini
D
D
Levitt
B
B
Sonnenblick
E H
EH
D000676:Amrinone / Q000494:pharmacology; D000818:Animals; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D020105:Milrinone; D009132:Muscles / Q000098:blood supply* / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D005082:Physical Exertion; D011728:Pyridones / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D014666:Vasomotor System / Q000187:drug effects / Q000503:physiopathology
D010726:Phosphodiesterase Inhibitors; D011728:Pyridones; D020105:Milrinone; D000676:Amrinone